Haleon (HLN) Non-Current Debt (2021 - 2025)
Haleon (HLN) posted Non-Current Debt of $10.3 billion for Q4 2025, down 6.76% on a QoQ basis from $11.1 billion in Q4 2024, and down 6.76% year-over-year from $11.1 billion in Q4 2024.
Haleon (HLN) Non-Current Debt (2021 - 2025) Analysis & Trends
Haleon's Non-Current Debt history runs 5 years deep, the most recent figure standing at $10.3 billion for Q4 2025.
- Quarterly Non-Current Debt fell 6.76% year-over-year to $10.3 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.3 billion (down 6.76% YoY) and the FY2025 annual result came in at $10.2 billion, down 7.2% from the prior year.
- Non-Current Debt was $10.3 billion for Q4 2025 at Haleon, down from $11.1 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $11.7 billion in Q4 2022 and bottomed at -$12.5 billion in Q2 2022.
- A 5-year average of $1.4 billion and a median of $5.2 billion in 2021 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt surged 9904.36% — and 2023, when it retreated 6.91%.
- Haleon's Non-Current Debt stood at $117.3 million in 2021, then jumped by 9904.36% to $11.7 billion in 2022, then fell by 6.91% to $10.9 billion in 2023, then increased by 1.53% to $11.1 billion in 2024, then decreased by 6.76% to $10.3 billion in 2025.
- Business Quant data shows HLN's Non-Current Debt at $10.3 billion in Q4 2025, $11.1 billion in Q4 2024, and -$9.3 billion in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 197.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.34 Bn |
| Dec 31, 2024 | 11.09 Bn |
| Jun 30, 2024 | -9.35 Bn |
| Dec 31, 2023 | 10.92 Bn |
| Jun 30, 2023 | -10.97 Bn |
| Dec 31, 2022 | 11.73 Bn |
| Jun 30, 2022 | -12.49 Bn |
| Dec 31, 2021 | 117.28 Mn |